Gilead wins legal battle over HIV drug as Eli Lilly opens early access program for obesity therapy retatrutide

Gilead Sciences secured a court victory concerning one of its HIV medicines, according to the brief report. The ruling resolves a legal dispute that had been pending, allowing the company to continue marketing the product without further interruption.

Eli Lilly announced that it will broaden the special‑access pathway for its experimental obesity drug retatrutide. After previously granting a single 79‑year‑old patient early access, the company now invites additional patients to apply for the program, aiming to expand availability while the therapy remains under investigation.

The updates were part of a roundup highlighting recent biotech developments, including earnings reports from major players and other regulatory news affecting the sector.